BDSX
BIODESIX INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$23.40
−1.10%Oct 19, 2026, 10:00 UTC
BIODESIX INC announced a partnership with Vanderbilt University and Vanderbilt University Medical Center to accelerate development of a radiomics-based test for lung nodule risk assessment.
Source:Sep 24, 2026, 10:00 UTC
Biodesix announced two complementary approaches to molecular residual disease (MRD) monitoring, a tumor-informed program and a tumor-naïve program, drawing on its bioinformatics and diagnostics test development expertise.
Source:Aug 5, 2026, 20:01 UTC
Biodesix reported second quarter 2026 revenue of $26.9 million, a 34% increase year over year, with an 82% gross margin, and maintained its full-year 2026 revenue guidance of $108-114 million.